Antiangiogenic approach in soft-tissue sarcomas
Authors:
- Juan Martin-LiberalJMJuan Martin-Liberal
- Ian JudsonIJIan Judson
- Charlotte BensonCBCharlotte Benson
- 1 August 2013
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 13 (8) , 975-982
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 2012
- Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) studyAnnals of Oncology, 2012
- Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT).Journal of Clinical Oncology, 2011
- Trends in survival for patients with metastatic soft‐tissue sarcomaCancer, 2010
- Renal cell carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-upAnnals of Oncology, 2009
- Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcomaBritish Journal of Surgery, 2004
- Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcomaJournal of Cancer Research and Clinical Oncology, 2004
- Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patientsEuropean Journal of Cancer, 2002
- Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcomaJournal of Cancer Research and Clinical Oncology, 1999
- Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group StudyJournal of Clinical Oncology, 1999